Breast cancer in transgender patients: A systematic review. Part 1: Male to female.

@article{Hartley2018BreastCI,
  title={Breast cancer in transgender patients: A systematic review. Part 1: Male to female.},
  author={Rebecca L. Hartley and Jill P Stone and Claire Temple-Oberle},
  journal={European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology},
  year={2018},
  volume={44 10},
  pages={
          1455-1462
        }
}

Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands

In trans women, the risk of breast cancer increased during a relatively short duration of hormone treatment and the characteristics of the breast cancer resembled a more female pattern, suggesting that breast cancer screening guidelines for cisgender people are sufficient for transgender people using hormone treatment.

Integrative review on breast cancer screening in the transgender population: what do we know?

This integrative review was to present the proposals for breast cancer screening in the transgender population, based on the literature, being searched in the Medline, PubMed, SciELO, and Lilacs databases.

Breast Cancer Risk and Screening in Transgender Individuals

The risk of breast cancer development in transgender individuals is different compared to that of the cis-gender population, and further prospective data are needed to appropriately quantify these risks and to assess what is the appropriate breast cancer screening recommendations for this population.

An Update on the General Features of Breast Cancer in Male Patients—A Literature Review

There are clear familial tendencies, with a higher incidence among men who have a large number of female relatives with breast cancer and (d) major inheritance susceptibility, among the predisposing risk factors for male breast cancer.

Breast Cancer in Transgenders: Narrative Review

There are no international guidelines on screening and management of transgender patients but it appears that breast screening before cosmetic mastectomy, exposure to hormonal therapy for more than 5 years, and as per natal women screening guidelines should be offered to the patient with detailed discussion on the harms and benefits of the same.

A Single-Center Study of Adherence to Breast Cancer Screening Mammography Guidelines by Transgender and Non-Binary Patients

The screening rates among the T GNB DFAB and TGNB DMAB groups did not significantly differ from one another, and univariate analyses showed no significant predictors for mammography.

Triple Negative Breast Cancer in a Male to Female Transgender Patient: A Case Report and Literature Review

ACR Appropriateness Criteria® Transgender Breast Cancer Screening.

References

SHOWING 1-10 OF 43 REFERENCES

Incidence of breast cancer in a cohort of 5,135 transgender veterans

It appears that TG veterans do not display an increase in breast cancer incidence, consistent with European studies of longer duration that conclude that CSH treatment in gender dysphoric patients of either birth sex does not result in a greater incidence than the general population.

Breast cancer in male-to-female (MtF) transgender patients: is hormone receptor negativity a feature?

A 41-year-old male-to-female (MtF) transgender patient presented with a symptomatic tender lump in the left breast and was referred to the oncologist for adjuvant chemotherapy and radiotherapy.

Breast cancer in male-to-female transsexuals: use of breast imaging for detection.

Screening for breast cancer in male-to-female transsexuals should be undertaken for those with additional risk factors (e.g., family history, BRCA2 mutation, Klinefelter syndrome) and should be available to those who desire screening, preferably in a clinical trial.

Clinicopathological study of breast tissue in female-to-male transsexuals

It is suggested that androgen does not alter the risk of carcinoma developing in the mammary glands of female-to-male transsexual (FTMT) women.

Breast cancer in a male-to-female transsexual patient with a BRCA2 mutation.

This is the first case of a BRCA2 mutation predisposing to breast cancer in a MtF transgender patient who developed breast cancer after 7 years of cross-sex hormonal therapy.

Breast cancer development in transsexual subjects receiving cross-sex hormone treatment.

Cross-sex hormone treatment of transsexual subjects does not seem to be associated with an increased risk of malignant breast development, in either MtF or FtM transsexual individuals.

Examining the Role of Screening Mammography in Men at Moderate Risk for Breast Cancer: Two Illustrative Cases

Two cases of breast cancer in men with moderate risk factors are reported to highlight potential gaps in screening guidelines and suggest a subset of men with elevated risk who might benefit from periodic clinical breast examination (CBE) and possibly annual screening mammography.

A Review of the Oncologic and Surgical Management of Breast Cancer in the Augmented Breast: Diagnostic, Surgical and Surveillance Challenges

An evidence-based summary of recommendations has been produced to guide breast surgeons in managing this particular group of patients and patients can be reassured that the presence of an implant does not increase the risk of breast cancer developing or affect the prognosis if breast cancer does develop.

Triple negative breast cancer in a male‐to‐female transsexual

A case of an aggressive triple negative inflammatory breast cancer in a male‐to‐female transsexual with a complicated psychiatric history with significant antipsychotic use is reported.